InMed Pharmaceuticals Promotion and Compensation Letter to Eric Hsu (Senior Vice President, Pre-Clinical R&D)
InMed Pharmaceuticals, Inc. has promoted Eric Hsu to Senior Vice President, Pre-Clinical R&D, effective March 1, 2019. In recognition of his agreement to work full time, his base salary will increase to $290,000, and he will be granted an additional 255,000 stock options, subject to board approval. This letter outlines the new role, compensation, and option grant as part of his employment terms.
Exhibit 10.4.3
 | InMed Pharmaceuticals, Inc.
|
4 March 2019
Dear Eric Hsu,
On behalf of InMed’s Board of Directors, I am pleased to announce your promotion to Senior Vice President, Pre-Clinical R&D. Additionally, in recognition of your agreement to increase your work commitment to InMed to full time (100%), I am pleased to make the following changes to your compensation:
Base Salary - will increase to $290,000 effective March 1, 2019; and
Options - subject to approval by the Board of Directors, you will be issued an additional 255,000 options to purchase common shares in the Company as per the Company’s standard options policies, priced on or around the date of this letter.
On behalf of the entire Management Team and Board of Directors, thank you for your contributions to the Company’s success and we look forward to achieving more, together.
/s/ Eric A. Adams
Eric A. Adams President and CEO
InMed Pharmaceuticals Inc.
